Neuropathology of LSDs
E. Kolodny
DOI: https://doi.org/10.1111/j.1651-2227.2007.00201.x
2007-03-23
Acta Paediatrica
Abstract:Treatment of lysosomal storage diseases (LSDs) in which the primary pathology is located within the CNS is particularly challenging. In order to effectively deliver therapy, we must consider not only the potential for treatment to gain access to CNS tissues beyond the blood–brain barrier, but also the complex pathological cascades leading to disease and the specific cellular pathology to which treatment should be targeted. This requires a thorough knowledge of the CNS effects and concomitant functional changes for each LSD. Historically, investigations of CNS manifestations have relied upon autopsy and biopsy samples; however, sophisticated investigative methods have recently been developed that allow us to gain an even better understanding of CNS pathophysiology in these rare and life-threatening conditions. Results from studies using the latest techniques were explored in a workshop session on Neuropathology of LSDs at this symposium. As explained by Steven Walkley, an appreciation of the role of the lysosomal system in cell metabolism and homeostatic regulation is key to understanding the complex neuropathology of LSDs. Modern studies of lysosomes and their component proteins provide evidence to support a far greater role for these organelles in cell metabolism than traditionally thought. Specifically, recycling of complex molecules following lysosomal degradation is thought to play a critical role in cellular homeostasis. This is exemplified in Niemann–Pick disease type C (NPC), in which a deficiency of lysosomal proteins NPC1 and NPC2 results in failed retroendocytic recycling of cholesterol. Given that the normal by-products of cholesterol metabolism, the oxysterols, are known to play a key role in regulating cholesterol synthesis, it is believed that their absence may contribute to the cholesterol dyshomeostasis observed in NPC-affected neurons. In light of such findings, Dr Walkley proposed that new therapeutic approaches could be developed based on replenishing the missing downstream products of lysosomal action, or mimicking their activity with drugs that have a similar capacity to maintain normal neuronal function. A common clinical hallmark of LSDs involves changes to CNS morphology. Andreas Fellgiebel reported that in Fabry disease, microand macroangiopathic alterations in the brain, such as severe and progressive white matter lesions (WMLs), can occur from an early age (Fellgiebel et al., Lancet Neurol 2006; 5: 791–5). Based on the theory proposed by Moore and colleagues (Moore et al., Brain Res Bull 2003; 62: 231–40), it is hypothesized that WML development in Fabry disease may be the result of a multi-step process involving changes in interstitial water content of the deep white matter. Recently, a new magnetic resonance imaging (MRI) technique called diffusion-tensor imaging (DTI) has been developed, which measures water diffusion characteristics in the brain, allowing detection of changes that occur prior to the development of explicit WMLs. Using this technique, Dr Fellgiebel and colleagues were able to detect microstructural brain tissue alterations in patients with Fabry disease, even when conventional MRI scans showed white matter to be normal. In this respect, DTI may provide an early indication of CNS involvement, providing an opportunity for the initiation of therapy before irreversible damage has occurred. In conclusion, these authors highlight the importance of furthering our understanding of the neuropathology of LSDs. At the cellular level, it is becoming increasingly apparent that the lysosome should be regarded as a key coordinator of cellular metabolic pathways and, therefore, essential to neuronal function. Furthermore, methodological advances now enable us to detect early changes in cell and tissue morphology which may contribute to CNS manifestations in these diseases. The challenge now is to utilize these advances and provide more effective disease management that will ultimately improve the quality of life of patients with LSDs.